Precise Biometrics (PREC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
Achieved positive EBITDA and operating cash flow for the full year despite a challenging environment marked by geopolitical uncertainty, negative currency effects, and delayed customer production volumes.
Revenue and earnings were negatively impacted by a major mobile customer postponing Q4 production to 2026 and a weaker USD.
Strategic and operational changes were implemented, and new projects and customers were secured in key segments.
Financial highlights
Q4 net sales: SEK 17.0 million, down 21.9% year-over-year; full-year net sales: SEK 77.8 million, down 10.4%.
Q4 EBITDA: SEK -1.9 million (vs. 3.4 million prior year); full-year EBITDA: SEK 0.2 million (vs. 13.4 million prior year).
Q4 EBIT: SEK -6.7 million; full-year EBIT: SEK -20.1 million.
Q4 earnings per share: SEK -0.08; full-year: SEK -0.25.
Q4 operating cash flow: SEK -3.2 million; full-year: SEK 1.9 million.
Annual Recurring Revenue (ARR) at year-end: SEK 18.9 million, stable year-over-year.
Outlook and guidance
Production volumes postponed to 2026 are expected to support growth in the first half of 2026.
The company is well-positioned for future growth with a strong product portfolio and new market opportunities, especially in mid-segment mobile phones and AI-based biometric software.
Focus remains on growth and maintaining positive cash flow in 2026.
Latest events from Precise Biometrics
- Merger forms a global biometrics leader, targeting SEK 45 million in annual synergies by 2027.PREC
M&A announcement23 Mar 2026 - Positive EBITDA and stable ARR amid lower sales, with strong demand for biometric solutions.PREC
Q3 202514 Nov 2025 - Q2 saw stable sales and new biometric projects, but profitability was pressured by currency and customer shifts.PREC
Q2 202515 Aug 2025 - Q3 delivered strong growth, positive EBIT, and record margins, with robust outlook ahead.PREC
Q3 202413 Jun 2025 - Net sales and EBITDA rose, with ARR and new projects supporting growth outlook.PREC
Q2 202413 Jun 2025 - Fifth straight quarter of growth and positive EBITDA, with strong outlook for 2025.PREC
Q4 20245 Jun 2025 - Net sales fell 7.7% in Q1 2025, but growth prospects remain strong for the year.PREC
Q1 20255 Jun 2025